Skip to main content
    P

    Pfizer Inc (PFE)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $29.80
    -0.24 (-0.78%)

    Market Cap: $171.16B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    92%(36/39)
    Avg Surprise
    +20.73%
    Streak
    22 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.73
    Range$0.56 - $0.84
    19 analysts
    EPS Revisions
    1
    0
    7d
    1
    6
    30d
    EPS Estimate DriftChange to current
    90d ago$0.82-10.8%
    60d ago$0.76-3.4%
    30d ago$0.76-3.4%
    7d ago$0.74-1.3%
    Current$0.73
    Revenue Consensus
    $15.9B
    Range$14.7B - $16.9B
    17 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.82
    Range$0.74 - $0.93
    25 analysts
    Revenue Consensus
    $18.1B
    Range$17.1B - $19.2B
    25 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.82---
    Sep 26EST
    		-$0.73---
    Jun 26
    Reported Aug 4
    		$0.77$0.68+13.24%Beat-1.3%
    Mar 26
    Reported May 5
    		$0.75$0.72+4.17%Beat-18.5%
    Dec 25
    Reported Feb 3
    		$0.66$0.57+15.79%Beat+4.8%
    Sep 25
    Reported Nov 4
    		$0.87$0.63+38.10%Beat-17.9%
    Jun 25
    Reported Aug 5
    		$0.78$0.57+36.84%Beat+30.0%
    Mar 25
    Reported Apr 29
    		$0.92$0.67+37.31%Beat+12.2%
    Dec 24
    Reported Feb 4
    		$0.63$0.46+36.96%Beat+530.0%
    Sep 24
    Reported Oct 29
    		$1.06$0.61+73.77%Beat+723.5%
    Jun 24
    Reported Jul 30
    		$0.60$0.46+30.43%Beat-10.4%
    Mar 24
    Reported May 1
    		$0.82$0.51+60.78%Beat-33.3%
    Dec 23
    Reported Jan 30
    		$0.10$-0.18+155.56%Beat-91.2%
    Sep 23
    Reported Oct 31
    		$-0.17$-0.34+50.00%Beat-109.6%
    Jun 23
    Reported Aug 1
    		$0.67$0.58+15.52%Beat-67.2%
    Mar 23
    Reported May 2
    		$1.23$0.99+24.24%Beat-24.1%
    Dec 22
    Reported Jan 31
    		$1.14$1.04+9.62%Beat+5.6%
    Sep 22
    Reported Nov 1
    		$1.78$1.40+27.14%Beat+32.8%
    Jun 22
    Reported Jul 28
    		$2.04$1.78+14.61%Beat+90.7%
    Mar 22
    Reported May 3
    		$1.62$1.57+3.18%Beat+74.2%
    Dec 21
    Reported Feb 8
    		$1.08$0.87+24.14%Beat+157.1%
    Sep 21
    Reported Nov 2
    		$1.34$1.09+22.94%Beat+86.1%
    Jun 21
    Reported Jul 28
    		$1.07$0.98+9.18%Beat+37.2%
    Mar 21
    Reported May 4
    		$0.93$0.78+19.23%Beat+16.3%
    Dec 20
    Reported Feb 2
    		$0.42$0.46-8.70%Miss-23.6%
    Sep 20
    Reported Oct 27
    		$0.72$0.71+1.41%Beat-4.0%
    Jun 20
    Reported Jul 28
    		$0.78$0.66+18.18%Beat-2.5%
    Mar 20
    Reported Apr 28
    		$0.80$0.73+9.59%Beat-5.9%
    Dec 19
    Reported Jan 28
    		$0.55$0.58-5.17%Miss-14.1%
    Sep 19
    Reported Oct 29
    		$0.75$0.62+20.97%Beat-3.8%
    Jun 19
    Reported Jul 29
    		$0.80$0.75+6.67%Beat-1.2%
    Mar 19
    Reported Apr 30
    		$0.85$0.75+13.33%Beat+10.4%
    Dec 18
    Reported Jan 29
    		$0.64$0.63+1.59%Beat+3.2%
    Sep 18
    Reported Oct 30
    		$0.78$0.75+4.00%Beat+16.4%
    Jun 18
    Reported Jul 31
    		$0.81$0.74+9.46%Beat+20.9%
    Mar 18
    Reported May 1
    		$0.77$0.74+4.05%Beat+11.6%
    Dec 17
    Reported Jan 30
    		$0.62$0.56+10.71%Beat+31.9%
    Sep 17
    Reported Oct 31
    		$0.67$0.65+3.08%Beat-
    Jun 17
    Reported Aug 1
    		$0.67$0.66+1.52%Beat-
    Mar 17
    Reported May 2
    		$0.69$0.67+2.99%Beat-
    Dec 16
    Reported Jan 31
    		$0.47$0.51-7.84%Miss-

    Dividends

    Dividend Metrics

    Forward Yield5.77%
    Forward Annual Dividend$1.72
    Payout Ratio73.15%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+2.44%
    5Y CAGR+2.50%
    PFE dividend history and ex-dividend datesRun PFE in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio9.77EV/EBITDA21.50x
    Price/FCF15.46xFCF Yield6.47%
    Profitability
    Profit Margin6.80%Operating Margin27.90%
    ROE5.01%ROIC2.84%
    Financial Health
    Debt/Equity0.74xInterest CoverageN/A
    Current Ratio1.27xQuick Ratio0.96x
    Trading Statistics
    Beta0.28Avg Volume29.55M
    52-Week High$30.4452-Week Low$22.57

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$29.62
    SMA 20$28.84
    SMA 50$28.36
    SMA 200$26.29
    EMA 10$29.59
    EMA 20$29.11
    EMA 50$28.21
    EMA 200$26.39

    MACD

    Line: 0.58Signal: 0.46Hist: 0.12

    ADX

    ADX: 28.9+DI: 30.6-DI: 13.7

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down40.0
    PSAR$28.53

    Bollinger Bands

    Upper Band$30.73
    Lower Band$26.95
    %B Position1308%(Upper)
    Band Width0.75

    RSI (14-Day)

    Neutral
    61.9

    Momentum Oscillators

    Stoch %K88.3
    Stoch %D91.2
    Williams %R-21.8
    ROC (10d)4.9%
    Momentum1.40
    CCI (20d)88.6
    MFI (14d)51.3

    Volatility Measures

    ATR (14d)$0.56(1.9%)
    StdDev (20d)0.94
    Hist Vol21.1%(Moderate)

    Volume Flow

    VWAP$29.94
    OBV1.1B
    AD Line-40.9B
    CMF (20d)0.047

    Volume Metrics

    Avg Vol (20d)29.8M
    Vol Ratio0.8x
    VWMA (20d)$28.81

    Pivot Points

    R3$30.81
    R2$30.56
    R1$30.30
    Pivot Point$30.05
    S1$29.79
    S2$29.54
    S3$29.28

    Advanced Oscillators

    TSI30.06
    Ultimate Osc57.1
    KST45.78

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$15.03B$14.45B$17.56B$16.65B$14.65B$13.71B$17.76B$17.70B$13.28B$14.88B$14.57B$13.49B
    Cost of Revenue$4.09B$3.55B$5.27B$4.17B$3.78B$2.85B$5.91B$5.26B$3.30B$3.38B$7.56B$9.27B
    Gross Profit$10.94B$10.90B$12.29B$12.48B$10.88B$10.87B$11.85B$12.44B$9.98B$11.50B$7.01B$4.22B
    Operating Expenses$7.88B$6.87B$9.41B$8.63B$7.09B$7.13B$9.51B$7.48B$8.98B$7.40B$11.29B$7.39B
    R&D$2.83B$2.63B$3.42B$3.94B$2.48B$2.21B$3.12B$2.61B$2.70B$2.49B$2.89B$2.78B
    SG&A$3.41B$2.96B$4.16B$3.19B$3.42B$3.03B$4.27B$3.24B$3.72B$3.50B$4.58B$3.28B
    Operating Income$3.06B$4.03B$2.87B$3.85B$3.78B$3.74B$2.35B$4.96B$1.00B$4.10B$-4,288,000,000$-3,171,000,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$3.72B$862.00M$4.51B$517.00M$739.00M$953.00M$2.36B$244.00M$1.11B$681.00M$0$181.00M
    Income Before Tax$-653,000,000$3.17B$-1,643,000,000$3.33B$3.04B$2.79B$-10,000,000$4.71B$-103,000,000$3.42B$-4,129,000,000$-3,352,000,000
    Income Tax Expense$-407,000,000$461.00M$-2,000,000$-216,000,000$141.00M$-189,000,000$-421,000,000$234.00M$-134,000,000$293.00M$-795,000,000$-964,000,000
    Net Income$-237,000,000$2.70B$-1,639,000,000$3.55B$2.93B$2.97B$418.00M$4.47B$48.00M$3.12B$-3,360,000,000$-2,376,000,000
    EBITDA$970.00M$4.78B$44.00M$5.00B$4.67B$4.40B$1.78B$6.47B$1.63B$5.16B$-2,459,000,000$-1,792,000,000
    EBIT$-652,000,000$3.17B$-1,643,000,000$3.33B$3.04B$2.79B$-11,000,000$4.72B$-104,000,000$3.42B$-4,129,000,000$-3,352,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Follow The Money And The Meter: Our Midterm Playbook For The Tech Trade

    Democratic majorities gain oversight and funding levers - vetoes and the filibuster make sweeping legislation unlikely without White House cooperation Mid-Oct odds: Kalshi 90% House...

    Leo Nelissen
    •
    10/27/26
    •
    74
    AI Infrastructure, Data Centers, Power Infrastructure, hyperscalers
    Also mentions:
    AZNLLYPFEAMZNGOOGL

    Pfizer: The 6.5% Yield Everyone Is Afraid To Trust

    Last raise was Dec 12, 2024 to $0.43, Dec 2025 declared $0.43 - quarterly rate at $0.43 for six quarters, calendar 2026 pays $1.72 vs 2025, next governance test is the Dec 2026 declaration Dividend costs about $9.8bn annually, based on 5.7bn shares and $1.72 per share...

    Leo Nelissen
    •
    8/17/26
    •
    261
    Dividend Investing, high-yield investing

    The Biggest Healthcare Disconnect In Decades - And The Stocks I’m Watching

    Healthcare has hit a 26-year relative low, but weakness alone does not make the sector a buy. AI-led capital flows, patent cliffs, IRA pricing pressure, and GLP-1 disruption explain much of the selloff. I prefer selective exposure: picks-and-shovels, AI-driven platforms...

    Leo Nelissen
    •
    5/25/26
    •
    466
    Healthcare Stocks, Dividend Investing, value investing
    Also mentions:
    TMOWSTLLYISRGPFE

    Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

    Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22...

    Glenn Ford
    •
    2/12/26
    •
    178
    Income Investing, value investing
    Also mentions:
    MRKBMYGILDABBV

    Volatility Is Not a Sell Signal: The Framework That Stops Panic Selling

    A 15% vol stock can easily swing 35% up or down in a year; volatility measures dispersion, not ceiling on movement Short-term price moves are 95%+ noise...

    Glenn Ford
    •
    2/5/26
    •
    141
    Income Investing, Risk Management
    Also mentions:
    OPFETMO

    Government Contracts

    Gov Obligations (TTM)
    -$546677
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    86.9%
    Active Awards
    1,017
    New Awards (TTM)
    1,014
    Avg Remaining Term
    9.2 mo

    Top agency: Department of Defense at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    SPE2D025F0634Department of DefenseDefense Logistics Agency$787275Aug 26, 2025
    75A50326F63004Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$542605May 15, 2026
    SPE2D325F428SDepartment of DefenseDefense Logistics Agency$24723Sep 17, 2025
    SPE2D326F056YDepartment of DefenseDefense Logistics Agency$22620Apr 23, 2026
    SPE2D326F4298Department of DefenseDefense Logistics Agency$22469Jan 23, 2026
    SPE2D326F9906Department of DefenseDefense Logistics Agency$14837Apr 8, 2026
    SPE2D326F4471Department of DefenseDefense Logistics Agency$9048Jan 26, 2026
    SPE2D326F6096Department of DefenseDefense Logistics Agency$8208Feb 18, 2026
    SPE2D325F334XDepartment of DefenseDefense Logistics Agency$3808Aug 20, 2025
    SPE2D325F303VDepartment of DefenseDefense Logistics Agency$3725Aug 7, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Pfizer's ELREXFIO meets Phase 3 myeloma endpoint

    Pfizer's ELREXFIO demonstrated superior progression-free survival compared to standard regimens in a Phase 3 trial for previously treated multiple myeloma. While the study met its primary endpoint...

    Mugglehead Investment Magazine•10/27/26•Somewhat-Bullish

    Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting

    Pfizer announced positive late-stage trial results for its multiple myeloma drug, Elrexfio (elranatamab), when administered in an earlier treatment line for the blood cancer. The company indicated that the Phase 3 trial...

    Seeking Alpha•10/27/26•Bullish

    Pfizer’s Elrexfio shows progression-free survival benefit

    Pfizer announced that its Phase 3 MagnetisMM-32 study for ELREXFIO (elranatamab) met its primary endpoint of progression-free survival in adults with relapsed or refractory multiple myeloma. The study showed...

    Investing.com•10/27/26•Bullish

    How EU Label Expansion Will Impact Ionis Stock

    Ionis Pharmaceuticals received a positive opinion from the EMA's CHMP for an expanded indication of TRYNGOLZA in the EU for severe hypertriglyceridemia...

    Simply Wall Street•10/27/26•Neutral

    Rare Disease Pharmaceutical Service Market Report Examines Industry Trends, Growth Drivers And Future Outlook

    The rare disease pharmaceutical service market is experiencing rapid growth, projected to reach $150.96 billion in 2026 with a 13.2% CAGR...

    openPR.com•10/27/26•Somewhat-Bullish

    PFE Valuation and Fair Value

    P/E
    9.8x
    Forward P/E
    9.6x
    EV/EBITDA
    21.5x
    P/FCF
    15.5x
    PEG
    12.8x
    P/B
    2.0x
    See GNG's fair value

    PFE Profitability: Margins, ROIC and FCF

    Gross margin
    73.2%
    Operating margin
    27.9%
    Net margin
    6.8%
    ROIC
    2.8%
    ROE
    5.0%
    FCF yield
    6.5%

    PFE Competitors

    CompanyTicker
    Novo Nordisk A/SNVO
    Danaher CorporationDHR
    Abbott LaboratoriesABT
    Intuitive Surgical IncISRG
    Gilead Sciences IncGILD
    Vertex Pharmaceuticals IncVRTX
    Amgen IncAMGN
    Bristol-Myers Squibb CompanyBMY

    Sector: Healthcare

    PFE Analyst Ratings

    Consensus
    Hold
    Analysts
    28
    Strong Buy
    2
    Buy
    8
    Hold
    16
    Sell
    1
    Strong Sell
    1

    PFE Bull Case vs Bear Case

    Bull case

    • PFE beat EPS estimates in 100.0% of its last 8 reported quarters.

    PFE Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    32.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.73
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 6 down

    PFE Dividend

    Forward yield
    5.8%
    Payout ratio
    73.1%
    3Y DPS growth
    2.4%
    5Y DPS growth
    2.5%
    Pay months
    Mar, Jun, Sep, Dec
    PFE dividend history

    Frequently Asked Questions About PFE

    What is PFE's current dividend yield?

    Pfizer Inc (PFE) has a forward dividend yield of 5.77%.

    Does PFE pay dividends?

    Yes, Pfizer Inc pays dividends with a forward dividend yield of 5.77%.

    What is PFE's P/E ratio?

    Pfizer Inc has a price-to-earnings (P/E) ratio of 9.77.

    What is PFE's market cap?

    Pfizer Inc (PFE) has a market capitalization of $171.16B with a current stock price of $29.80.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In